Canada markets closed

Evofem Biosciences, Inc. (EVFM)

OTC Markets OTCQB - OTC Markets OTCQB Delayed Price. Currency in USD
Add to watchlist
0.01090.0000 (0.00%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0109
Open0.0130
Bid0.0101 x 0
Ask0.0105 x 0
Day's Range0.0099 - 0.0151
52 Week Range0.0060 - 0.8200
Volume9,845,229
Avg. Volume1,324,519
Market Cap676,458
Beta (5Y Monthly)-0.74
PE Ratio (TTM)0.01
EPS (TTM)1.7400
Earnings DateAug 12, 2024 - Aug 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing

    MOUNTAIN VIEW, Calif., July 17, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12th, Aditxt, its wholly owned subsidiary Adifem, Inc., and Evofem Biosciences, Inc.’s ("Evofem") (OTCQB: EVFM) amended and restated their Merger Agreement. This amended and restated Merger Agreement, among others, addresses pre-closing issues critical for Evofem’s future success, including inter

  • PR Newswire

    Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare

    Women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman's unique needs, to offer Phexxi® (lactic acid, citric acid and potassium bitartrate), the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.

  • PR Newswire

    Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter

    Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,992,472, which covers composition and methods for contraception with a composition that encompasses Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel.